<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">So, Derek</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Point-of-Care Genetic Testing Facilitates Rapid Personalization of Antiplatelet Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">The primary objective of the Reassessment of Antiplatelet Therapy using an Individualized Strategy Based on Genetic Evaluation [RAPID GENE; NCT01184300] study was to evaluate the feasibility and test characteristics of a nurse-operated POC genetic test to determine CYP2C19*2 carrier status.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>